Skip to content

Myo-inositol Therapy on the Dynamics of Embryo Development in Patients Suffering From PCOS Undergoing ICSI Treatment

Evaluation Concerning the Influence of Myo-inositol Therapy on the Dynamics of Embryo Development in Patients Suffering From PCOS Undergoing ICSI Treatment

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02385396
Enrollment
217
Registered
2015-03-11
Start date
Unknown
Completion date
Unknown
Last updated
2015-03-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility, Polycystic Ovary Syndrome

Keywords

Polycystic Ovary Syndrome, Infertility, Myo-inositol, Intracytoplasmic sperm injection

Brief summary

The purpose of this study is to analyse the activity of myo-inositol on pregnancy rate, embryo development dynamics and oestradiol and progesterone concentration in blood serum and Superoxide Dismutase (SOD) and catalase concentration in follicular fluid of patients with Polycystic Ovary Syndrome (PCOS) undergoing Intracytoplasmic Sperm Injection (ICSI).

Interventions

DIETARY_SUPPLEMENTInofolic: myo-inositol and folic acid

4000 mg of myo-inositol and 0,4 mg of folic acid for 3 months preceding the ICSI procedure

Sponsors

Medical University of Lublin
Lead SponsorOTHER

Study design

Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
27 Years to 35 Years
Healthy volunteers
No

Inclusion criteria

ICSI treatment due to infertility PCOS patients enrolled according to the criteria established by representatives of the American Society of Reproductive Medicine (ASRM) and the European Society of Human Reproduction and Embryology (ESHRE)

Exclusion criteria

Severe endometriosis BMI \<17 and \>30 Metabolic diseases Lowered ovarian reserve

Design outcomes

Primary

MeasureTime frameDescription
Oestradiol (E2) level in blood serum (pg/ml)Between 11th and 19th day of cycle, when the largest of the oocyte in the evaluation of ultrasound exceeded 17mm diameter,
Progesterone (ng/ml) level in blood serumBetween 11th and 19th day of cycle, when the largest of the oocyte in the evaluation of ultrasound exceeded 17mm diameter
Superoxide dismutase (SOD) activity level in follicular fluid (mIU/mg)On puncture day or on collection day of oocytes, in practice, between 11th and 19th day of cycleThe decision was taken when three conditions are met: the biggest oocyte exceeds 17mm, the endometrium was over 9mm (two layers) and estradiol level was greater than 150
Catalase activity level in follicular fluid (mIU/mg)On puncture day or on collection day of oocytes, in practice, between 11th and 19th day of cycleThe decision was taken when three conditions are met: the biggest oocyte exceeds 17mm, the endometrium was over 9mm (two layers) and estradiol level was greater than 150

Secondary

MeasureTime frameDescription
Period of blastocyst and embryo developmentFrom the moment of puncture, between the 11th and 19th day of the cycle, for a maximum of seven daysEmbryo culture was evaluated by means of constant monitoring performed in 10-minute intervals with a camera placed inside the incubator.The t0 time was described as the hour of the ICSI. tF was defined as the first moment when pronuclei were already visible, whereas tC as the last moment of their visibility. The moment when a single cell embryo appeared after syngamy was determined as t1, and then the superseding divisions were marked as t2, t3, t4, t5, t6, t7, t8. tM stood for the beginning of morula formation, whereas tB was the time during which the first signs of blastocyst cavity could be seen.
Pregnancy rateDuring the 7th week of pregnancyUltrasound examination of the echo of the embryo and heart rate

Countries

Poland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026